Get to know our clinical trials
Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and tolerability of maridebart cafraglutide in adult participants without type 2 diabetes mellitus who are obese or overweight.
THIS STUDY IS BEING CONDUCTED TO TEST WHETHER MARIDEBART CAFRAGLUTIDE [MARITIDE (FORMERLY AMG 133)] IS A SAFE DRUG, CAN REDUCE BODY WEIGHT, AND CAN IMPROVE WEIGHT-RELATED CONDITIONS IN PEOPLE LIKE YOU WHO ARE LIVING WITH OBESITY OR BEING OVERWEIGHT, BUT DO NOT HAVE TYPE 2 DIABETES (T2DM, A DISEASE THAT OCCURS WHEN BLOOD SUGAR LEVELS ARE TOO HIGH).
Technical Summary
- PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MARIDEBART CAFRAGLUTIDE IN ADULT PARTICIPANTS WITHOUT TYPE 2 DIABETES MELLITUS WHO ARE OBESE OR OVERWEIGHT (MARITIME-1).
- Code EudraCT: 2024-515524-36
- Protocol number: 20210181
- Promoter: Amgen Inc.
- Molecule/Drug: Maridebart cafraglutida
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.